Clinical trial
AS703569 Phase I in Patients With Solid Tumours
NCT00391521 · EMD Serono, Industry · Completed
Key facts
| NCT number | NCT00391521 |
|---|---|
| Title | AS703569 Phase I in Patients With Solid Tumours |
| Official title | A Phase I Multicenter, Open-Label, Dose Escalation Trial of AS703569 Given Orally to Subjects With Solid Tumours |
| Lead sponsor | EMD Serono, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Tumors |
| Intervention type | Drug |
| Interventions | AS703569 |
| Enrollment | 104 |
| Start date | Aug 1, 2006 |
| Primary completion | Jun 1, 2010 |
| Completion | Jun 1, 2010 |
| First posted | Oct 24, 2006 |
| Last update posted | Jan 30, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: